Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 1/28: (ABMD) (FSL) (AAPL) (YHOO) Higher; (NBG) (ETH) (PBR) Lower (more...)
- Google (GOOGL) Will Open Predictive Search App to Third-Party Data
- Unusual 11 Mid-Day Movers 1/28: (ABMD) (PSTI) (FSL) Higher; (NBG) (BBG) (SALT) Lower
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!